On November 14, Wells Fargo CSI Pharmaceutical 50 ETF (515950) closed down 2.46%, with a turnover of 23.6889 million yuan.
Pharmaceutical Leading ETF (515950) was established on March 16, 2020, and the full name of the fund is Wells Fargo CSI Pharmaceutical 50 Exchange-traded Open-ended Index Securities Investment Fund, and the fund is referred to as Wells Fargo CSI Pharmaceutical 50 ETF. The fund has a management fee of 0.50% per annum and a custody fee of 0.10% per annum. The performance comparison benchmark of the leading pharmaceutical ETF (515950) is the return rate of the CSI Pharmaceutical 50 Index.
In terms of scale, as of November 13, the latest share of the leading pharmaceutical ETF (515950) was 833 million shares, and the latest scale was 778 million yuan. Looking back on December 29, 2023, the share of the leading pharmaceutical ETF (515950) was 923 million shares, and the scale was 905 million yuan. That is, the share of the fund has decreased by 9.75% and the scale has decreased by 14.08% since the beginning of this year.
In terms of liquidity, as of November 14, the cumulative turnover of the leading pharmaceutical ETF (515950) in the past 20 trading days was 652 million yuan, with an average daily turnover of 32.6109 million yuan, and since the beginning of this year, the cumulative turnover in 209 trading days has been 4.570 billion yuan, with an average daily turnover of 21.8681 million yuan.
The current fund manager of the Pharmaceutical Leading ETF (515950) is Wang Lele. Wang Lele has managed (or intends to manage) the fund since March 16, 2020, with a return of 6.05% during his tenure.
According to the latest regular report, the heavy stocks of the leading pharmaceutical ETF (515950) include Hengrui Pharmaceutical, WuXi AppTec, Mindray Medical, Pien Tze Huang, Aier Ophthalmology, United Imaging Medical, Kelun Pharmaceutical, Aimeike, Changchun High-tech, and Wantai Biotechnology, with the following proportions.
| stock symbol | ,stock name | ,position ratio | , number of shares held (shares). | Market value of the position (RMB). |
| 600276 | Hengrui Pharmaceutical | : 11.40%, | 1,738,409,917,100 | |
| 603259 | WuXi AppTec | ,10.10%, | 1,538,9057,430 | |
| 300760 | Mindray Medical | 8.99% | 244,771,697,100||
| 600436 | Pien Tze Huang | 5.95% | 183,600 | 47,458,800 |
| 300015 | Aier Ophthalmology | 5.67% | 2.842 million | 45.2165 million |
| 688271 | United Imaging Medical | 3.22% | 200,625,672,600 | |
| 002422 | Kelun Pharmaceutical | 2.74%, | 683,300 | , 21,865,600 |
| 300896 | Aimeike | ,2.72%, | 92,121,689,300 | |
| 000661 | Changchun High-tech | 2.71%, | 196,900 | , 21,637,300 |
| 603392 | Wantai Biotechnology | 2.38%, | 232,319,016,400 |
Risk Warning: The market is risky, and investment needs to be cautious. This article is automatically released by the AI model, and any information appearing in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, any form of expression, etc.) is for reference only and does not constitute personal investment advice. The MACD golden cross signal is formed, and these stocks are rising well!
Ticker Name
Percentage Change
Inclusion Date
